Shenfu injection attenuates lipopolysaccharide-induced myocardial inflammation and apoptosis in rats

• 来源期刊: 中国天然药物
• 学科: 医学
• 年，卷（期）: 2020,（3）
• 页码范围: 226-233
• 页数: 8页
• 分类号: R965
• 语种: 英文
• DOI: 10.1016/S1875-5364(20)30025-X

摘要

Shenfu injection (SFI),a Chinese medicinal product,shows potent efficacy in treating sepsis.The aim of the present study was to clarify the protective effects of SFI against lipopolysaccharide (LPS)-induced myocardial inflammation and apoptosis.Experiments were carried out in Sprague-Dawley (SD) rats treated with LPS or LPS + SFI,and in H9C2 cardiomyocytes.The sepsisassociated myocardial inflammation and apoptosis was induced by the intraperitoneal injection of LPS (20 mg·kg-1).SFI attenuated the increased expression of tumor necrosis factor (TNF)-a and interleukin (IL)-1β induced by LPS both in serum and heart.In LPS group,cell viability was reduced,and reversed after SFI administration.LPS treatment increased the expression levels of cleaved-caspase 3 and Bax,and those of Bcl2 and Bcl2/Bax.These two trends were reversed by SFI administration.The expression levels of phosphorylated mitogen-activated protein kinase kinase (p-MEK) and phosphorylated extracellular regulated protein kinases (p-ERK) were increased by LPS,and reversed by SFI.MEK inhibitor U0126 attenuated the apoptosis induced by LPS.These results indicate that SFI could treat LPS-induced cardiac dysfunction.In conclusion,SFI attenuates the inflammation and apoptosis induced by LPS via downregulating the MEK and ERK signaling pathways.